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Purpose: To investigate the possible differences between SPECT/CT based whole-remnant and
maximum-voxel dosimetry in patients receiving radio-iodine ablation treatment of differentiated
thyroid cancer (DTC).
Methods: Eighteen DTC patients were administered 1.11 GBq of 131I-NaI after near-total thyroidec-
tomy and rhTSH stimulation. Two patients had two remnants, so in total dosimetry was performed for
20 sites. Three SPECT/CT scans were performed for each patient at 1, 2, and 3–7 days after adminis-
tration. The activity, the remnant mass, and the maximum-voxel activity were determined from these
images and from a recovery-coefficient curve derived from experimental phantom measurements.
The cumulated activity was estimated using trapezoidal-exponential integration. Finally, the absorbed
dose was calculated using S-values for unit-density spheres in whole-remnant dosimetry and S-values
for voxels in maximum-voxel dosimetry.
Results: The mean absorbed dose obtained from whole-remnant dosimetry was 40 Gy (range
2–176 Gy) and from maximum-voxel dosimetry 34 Gy (range 2–145 Gy). For any given patient,
the activity concentrations for each of the three time-points were approximately the same for the two
methods. The effective half-lives varied (R= 0.865), mainly due to discrepancies in estimation of
the longer effective half-lives. On average, absorbed doses obtained from whole-remnant dosimetry
were 1.2±0.2 (1 SD) higher than for maximum-voxel dosimetry, mainly due to differences in the
S-values. The method-related differences were however small in comparison to the wide range of
absorbed doses obtained in patients.
Conclusions: Simple and consistent procedures for SPECT/CT based whole-volume and maximum-
voxel dosimetry have been described, both based on experimentally determined recovery coefficients.
Generally the results from the two approaches are consistent, although there is a small, systematic
difference in the absorbed dose due to differences in the S-values, and some variability due to
differences in the estimated effective half-lives, especially when the effective half-life is long. Irre-
spective of the method used, the patient absorbed doses obtained span over two orders of magnitude.
C 2016 American Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4961742]
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1. INTRODUCTION
Administration of 131I-NaI for postoperative ablation of
thyroid remnants for the treatment of differentiated thyroid
cancer (DTC) has been commonly accepted since the 1940s.1
Activities of 1.11–3.7 GBq are usually administered2 and
a number of studies have dealt with the outcome of the
treatment.3–10 The absorbed dose to thyroid remnants has
been investigated11–20 leading to a wide range of mean values
per unit of administered activity, e.g., 28,18 65,19 93,13,14
and 322 Gy/GBq.15 Maxon et al.,11 O’Connell et al.,14 and
Flux et al.,18 correlated the absorbed dose to the outcome of
the treatment, reporting values of absorbed dose to thyroid
remnants above which there is a significant probability of
successful ablation. Maxon et al.11 reported a value of 300 Gy,
whereas O’Connell et al.14 and Flux et al.,18 gave more similar
values of 60 and 49 Gy, respectively.
A plausible explanation for the wide range of the ab-
sorbed doses reported, are differences in methodology for
imaging, activity quantification, and dosimetry. In previous
studies, imaging modalities included rectilinear scans with
one head11,13,15 or two heads,14 gamma-camera imaging in
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planar12,16,19 or SPECT acquisition mode,18 and PET/CT
scanning.17,20 Dosimetry has been based on tracer studies
of 131I11,13,15,16 or 124I,17,20 or therapy studies.12,14,16,18,19 In
most cases at least three scans have been acquired, although
one study reported up to nine scans.12 The timing of the
scans has differed, and the last imaging time-point has varied
between 3 and 14 days after administration. For determination
of the cumulated activity, different approaches have been
followed, such as using an effective half-life retrieved from
the literature,17 a monoexponential time-activity curve deter-
mined from data,14,15 a curve including several phases,12,19,20
or a trapezoidal integration and a monoexponential curve
for extrapolation beyond the last data point.16,18 Methods
used for determination of the thyroid remnants mass have
also varied and mass has been estimated using the cross-
sectional area in planar images,11,13–16,19 anterior- and lateral-
view imaging,12 or iterative thresholding methods.14,17,18,20
Usually the whole-remnant has been considered to perform
dosimetry. However, Flux et al.18 introduced maximum-voxel
dosimetry, i.e., dosimetry using the voxel of maximum counts
in SPECT images.
131I SPECT/CT imaging is now widely available. The
absorbed dose to thyroid remnants can therefore be performed
with whole-volume or maximum-voxel based methods. The
aim of this study was to investigate the possible differences
between these two approaches. For this purpose, a straight-
forward calibration-based procedure was developed, based on
SPECT/CT imaging and basic quality-control phantoms. The
recovery-coefficient curve derived in this method was applied
for both whole-volume and maximum-voxel dosimetry in
20 sites of radio-iodine uptake in 18 patients.
2. METHODS
2.A. Data collection and processing
2.A.1. Patient data and imaging
Data included 18 patients (14 female and four male)
treated for low-risk DTC (Refs. 1 and 2) with 1.11 GBq
of 131I-NaI after stimulation with rhTSH. In two patients,
there were two remnants with radio-iodine uptake, so in total
dosimetry of 20 sites was performed. Prior to therapy, patients
had undergone a near-total or complete thyroidectomy.
After radio-iodine administration, patients remained 24 h
as inpatients and were released when the dose-rate at 1 m
was below 40 mSv/h, according to recommendations of the
IAEA.21 Informed consent was obtained from all patients.
Three SPECT/CT acquisitions centered on the neck region
were performed for each patient. Imaging times were at 1, 2,
and 3–7 days after administration. The time of the third acqui-
sition varied because acquisitions were not performed during
weekends and depending on the availability of the gamma
camera. SPECT/CT acquisitions were performed employing
a dual-head General Electric (GE, Fairfield, CT, USA) Infinia
Hawkeye gamma camera, with a crystal thickness of 9.5 mm
and equipped with High-Energy General-Purpose collimators.
A helical CT of pitch 1.9 was performed using 120 kVp
(the lowest available value), 2 mA, and a rotation velocity of
2.6 rpm. The CT was used for SPECT attenuation correction.
SPECT projections were acquired in 60 angles. For the first
two patients, the projection time was 60 s, while for the other
patients it was 45 s due to limited availability of the gamma
camera. A matrix size of 128×128 was used, and a voxel
size of 0.4423 cm3. A photopeak energy window centered at
364 keV and 20% in width was used. For scatter correction,
a dual energy window method implemented by GE was
performed, with an additional window centered at 297 keV and
20% in width. SPECT image reconstruction was performed
using the ordered subsets expectation maximization algorithm
in a Xeleris work station of GE, with two iterations and ten
subsets, applying a Butterworth filter with critical frequency
0.5 cycles/cm and power 10 (order 5). Analysis of SPECT
images was performed using the ImageJ program (NIH,
Bethesda, MD, USA). Figure 1 shows an example of patient
SPECT images from three sequential time-points.
2.A.2. Phantom measurements and simulations
Two phantoms were used for calibration and method
development: a cylindrically shaped phantom of 4 l (diameter
15.5 cm and height 21.2 cm) filled with an aqueous solution
of 131I-NaI; and the IEC-Standard 61675-1 image-quality
phantom22 in which the six spheres of volumes 0.5, 1.2, 2.6,
5.6, 11.5, and 26.5 cm3 were filled with an aqueous solution of
131I-NaI. The activity concentration in the spheres ranged be-
tween 0.4 and 2.3 MBq/cm3, as measured in a dose calibrator
Capintec CRC®-15R (Capintec, Inc., Ramsey, NJ, USA).
SPECT/CT acquisition of the elliptically shaped phantom
was performed using the same acquisition parameters as
for patients, and the total number of counts in a volume
corresponding to the physical phantom volume was deter-
mined. This value was divided by the acquisition time and
the contained activity, giving the calibration factor, ε, in
unit cps/MBq. For the IEC phantom measurements, four
SPECT/CT acquisitions were performed using the same
parameters as used for patients with the exception of the time
per projection, which was either 10 or 15 s. The results of
the reconstructions of the four acquisitions were averaged in
order to reduce the uncertainty of the acquisitions.
F. 1. The central part of reconstructed SPECT images focused on the site
with radio-iodine uptake for one patient. Images shown, from left to right,
were acquired at 1, 2, and 4 days after administration and are in the same
greyscale.
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In addition to phantom measurements, computer simula-
tions of imaging were performed. Voxelized, approximately
spherically shaped, objects with uniform activity concen-
tration were defined centrally in 3D image matrices. To
mimic effects of limited spatial resolution, these images were
convolved with a 3D Gaussian function whose full-width at
half maximum (FWHM) was defined to three, four, and five
times the voxel dimensions of the patient SPECT images,
thus corresponding to 13.3, 17.7, and 22.1 mm, respectively.
These FWHMs were selected to mimic the reconstructed
resolution of real gamma camera systems. For the camera
system used herein, the FWHM of the point-spread function
(PSF) was measured to be 19 mm. These simulations were
performed in Interactive Data Language, version 8.4 (Exelis
Visual Information Solutions, Inc.).
2.B. Dosimetry of sites with radio-iodine uptake
2.B.1. Recovery coefficients for homogenous
spherical objects
In order to quantify the activity concentration in small
volumes, a common approach is to apply recovery coefficients
to compensate for effects of limited resolution. Appendix A
shows the method followed to determine the volume of
spherical objects with homogeneous activity concentration by
using recovery coefficients.
2.B.2. Whole-volume dosimetry (Method 1)
The consistency between measurements in the elliptically
shaped phantom and the IEC phantom spheres was first
checked. For the four acquisitions of the IEC phantom, the
counts originating from each sphere were determined by
drawing a rough VOI around the sphere and applying a
5% threshold to exclude counts from septal penetration and
scatter. The sphere activity was then determined by dividing
the total counts by the acquisition time and the calibration
factor, ε, determined from the 4 l-calibration phantom. Using
this procedure the sphere activities could be determined to
within 10% from the inserted activities measured in the dose
calibrator.
The whole volume of the site of radio-iodine uptake was
considered for dosimetry. To determine the activity from
patient SPECT images, the sites were roughly delineated with
a margin, and a threshold of 30% was applied to discriminate
against activity in surrounding tissues. Thresholds of 20%
and 40% were also investigated, obtaining similar results,
and a value of 30% was chosen as a compromise to avoid
background counts while maintaining a sufficient count level.
The total count rate, C30, was determined and the site activity,
As, was calculated according to
As =
C30
ε f30
. (1)
The parameter f30 was introduced to compensate for the loss of
count rate resulting from applying the 30% threshold and was
determined based on the IEC phantom spheres as the ratio of
the total count rates when using a 30% threshold to that using a
5% threshold. For the IEC phantom data, it was observed that
in the volume range between 0.5 and 11.5 cm3 this ratio was
approximately constant and was obtained to be 0.59±0.03
(1 SD). For comparison, the f30 obtained from the simulated
sphere data were 0.61±0.03, 0.59±0.01, and 0.58±0.01, for
FWHMs of 13.3, 17.7, and 22.1 mm, respectively.
The activity As was determined for each of the consecutive
SPECT images, and the cumulated activity A˜s was calculated
by trapezoidal integration up to the last time-point, and
thereafter assuming a monoexponentially decaying activity
retention with an effective half-life determined from previous
time-points.16,18
The site volume, vs, was determined as described in
Appendix A, Eq. (A5), with vs in place of vo,
vs = RC (va,s) · va,s. (2)
The apparent site volume, va,s, was determined from patient
SPECT images. However, because of the background count
rate in surrounding tissues Eq. (A4) was less suited and va,s
was instead estimated following
va,s =∆v
C30
cm f30
. (3)
Each of the three SPECT images was evaluated, and the
mean va,s was calculated. The volume of the radio-iodine-
accumulating sites was then determined using Eq. (2), with
an RC determined for the mean va,s.
The whole-remnant absorbed dose, D1, was determined as
D1= A˜sSs← s(vs)/ρthyr, (4)
where Ss← s values in unit Gy MBq−1 h−1 were obtained
using a function Ss← s = 0.110× v−0.974s , which was derived
by interpolation of values for unit-density spheres.23 The mass
density was also taken into consideration24 and was considered
to be that of thyroid tissue (1.05 g/cm3).25
2.B.3. Maximum-voxel dosimetry (Method 2)
For patient SPECT images, the activity per voxel, Avx, was
estimated (see Appendix C) according to
Avx=
1
ε
cm
RC(va,s) . (5)
The cumulated activity per voxel, A˜vx, was calculated by
curve-fitting and integration according to the trapezoidal-
exponential method described above. The maximum-voxel
absorbed dose, D2, was determined following
D2= A˜vxSvx←vx
ρtis
ρthyr
, (6)
where Svx←vx was valid for the voxel size (a cubic voxel of
side 0.442 cm), originally given26 for soft tissue mass density,
ρtis, of 1.04 g/cm3. The factor ρtis/ρthyr was introduced to
compensate for differences in mass density24 to that of thyroid
(1.05 g/cm3).25 The density-scaled voxel S-value equaled
1.070 Gy/MBq h.
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3. RESULTS
Data from patient studies are presented as mean value
±1 SD (range, first quartile, median value, third quartile).
Values given in brackets are in the same unit as the mean.
The mean value of the mass of sites with 131I uptake
in all patients was (3.9±2.2) g (1.3–9.1, 2.4, 3.0, 5.3). At
1 day after administration, the remaining activity in these
sites, determined using Method 1, and the remaining activity
per voxel, determined using Method 2, were (6.0±4.0) MBq
(1.0–13.6, 3.2, 5.0, 9.1) and (0.19±0.18) MBq (0.02–0.75,
0.05, 0.16, 0.23), respectively. Figure 2 shows the activity
per mass at three times of SPECT/CT imaging, for Methods
1 and 2. The correlation coefficients R between results for
both methods were very close to 1, with values obtained for
the first, second, and third acquisitions of 0.994, 0.998, and
0.998, respectively.
The mean values of the effective half-lives obtained from
Methods 1 and 2 were similar, with results obtained of
(114±51) h (36–193, 73, 101, 149) and (117±48) h (36–193,
80, 113, 151), respectively. Figure 3 shows the effective half-
lives from Methods 1 and 2, with a correlation coefficient of
0.865. The mean value of the cumulated activity concentration
determined from Method 1 was also similar to that obtained
from Method 2, with values of (356 ± 407) MBq h g−1
(17–1578, 84, 209, 495) and (350±379) MBq h g−1 (16–1501,
83, 216, 563), respectively. The correlation coefficient for the
cumulated activity concentration obtained from Methods 1
and 2 was 0.986.
Figure 4(A) shows the ratio, D1/D2, of the absorbed dose
obtained from Methods 1 and 2 as function of the site mass as
estimated using Method 1. The mean value of these ratios was
obtained to be 1.2±0.2. Figure 4(A) also shows the interval
delimited by the mean value ±2 SDs. From the 20 values, 19
were within 2 SDs (95% of the values), which agreed with a
qualitative investigation (not shown) where the distribution of
the ratios was found to be close to a normal distribution. The
point with a value outside 2 SDs corresponds to the patient
with the highest ratio of the effective half-lives obtained from
Methods 1 and 2. For comparison, Fig. 4(A) also includes the
ratio of absorbed doses determined for the spheres of the IEC
phantom, as function of the sphere mass. This ratio increased
slightly with mass and was close to the mean-ratio value for
patients, confirming that there was a small, but systematic
difference between absorbed doses estimated using Methods
1 and 2. Figure 4(B) shows the absorbed dose ratio when the
contribution to the cumulated activity from the extrapolated
part, beyond the last data point, is excluded. The contribution
of the extrapolated part to the total cumulated activity was
between 3% and 76% for Method 1 and between 4% and 70%
for Method 2. It is seen that the main cause of the variability
between Methods 1 and 2 in Fig. 4(A) is the estimation of the
effective half-life.
Figure 5 shows a cumulative histogram of the number of
patients in whom different levels of absorbed doses to sites
were reached from Methods 1 and 2, respectively. The mean
absorbed doses obtained were (40± 46) Gy (2–176, 9, 23,
56) and (34± 37) Gy (2–145, 8, 21, 55), for Methods 1
F. 2. The activity per mass obtained from Methods 1 (vertical axis) and 2
(horizontal axis), for the three SPECT/CT acquisitions performed for most
patients at 1, 2, and 4 days after administration. The dashed line represents
the line of identity. N.B. Axes are in logarithmic scale for purpose of visual-
ization of data points.
and 2, respectively. Thus, although methodological differences
appeared to exist, with Method 2 giving slightly lower values
than Method 1, these differences were small in comparison to
the wide range of absorbed doses given.
4. DISCUSSION
Presently, most centers have the capability of 131I SPECT/CT
imaging. To promote dosimetry in DTC, it is of interest to
develop methods that can be easily applied in currently used
clinical platforms. Two approaches that have previously been
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F. 3. Effective half-lives from Method 1 (vertical axis) and Method 2
(horizontal axis). The dashed is the line of identity.
used for dosimetry are whole-volume and maximum-voxel
based methods.11,14,18 Practically, Method 2 has the advantage
of not having to determine the total activity in the remnant
by applying the thresholding procedure, but on the other
hand, the remnant absorbed dose is underestimated since the
contribution from neighboring voxels is disregarded. In this
study, the possible differences and similarities between these
methods have been investigated for 18 DTC patients and, in
total, 20 sites of radio-iodine uptake.
Determination of small volumes from nuclear medicine
images is severely limited by spatial resolution, and in context
of DTC dosimetry, the mass estimation is thought to be
the largest potential source of error.11 Currently there is no
standard method to determine the volume of sites of radio-
iodine uptake following surgery. In this study, the volume is
estimated using a procedure based on recovery coefficients
and the concept of apparent volume, representing the imaged
volume affected by spatial resolution. The procedure is robust
in the sense that does not rely on the site border as reflected
in the low-resolution SPECT images, and it can be easily
implemented on clinical work stations and can thus be applied
to all patients. The mean value of masses obtained was (3.9
±2.2) g which is similar to previously reported values: 2.5 g,12
F. 5. Cumulative histogram of the percentage of patients that reached
different absorbed doses to sites, as determined using Methods 1 and 2. N.B.
The x-axis is on a logarithmic scale.
3.1 g,14 4.1 g,15 1.9 g,16 and 6.6 g.27 The obtained volumes may
be considered high, but there are possible reasons for which the
obtained masses are higher than that of the tissue left directly
after surgery. Enlargement of thyroid tissue may occur as a
consequence of radiation thyroiditis,28 or due to stimulation
with rhTSH.29–31 Also, since patient acquisitions are made
without immobilization devices, motion-induced blurring may
produce an overestimated volume. The mass estimation is
also affected by uncertainties in the RC-calibration curve
(Fig. 7), mainly resulting from variability in the activities and
volumes of the radioactive solution in the calibration phantom,
and also the positioning of the phantom with regard to the
gamma camera, affecting the reconstructed spatial resolution.
Another methodological limitation is that the RC-calibration
curve is determined from spherical objects with homogenous
activity distributions and without surrounding activity, while
the geometry of sites with 131I uptake may be different and
exhibit heterogeneities in the activity distributions. Also some
background activity may be present, thus possibly affecting the
true recovery coefficient. The assumption of spherical shapes
is a starting point and is a commonly applied assumption,32
and the activity concentration in tissues surrounding thyroid
remnants is generally low. However for future studies, it is of
F. 4. (A) Ratio of absorbed doses when estimated using Methods 1 and 2 for patients as function of the site mass (black symbols), and for spheres in the IEC
phantom (open connected symbols) as function of sphere mass. Horizontal lines show the mean value for patients and the interval defined by the mean value
±2 SDs. (B) The same ratios as in (A) when excluding the extrapolated exponential part in the integration of cumulated activity in sites of uptake.
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F. 6. Absorbed dose per unit of cumulated activity as function of mass,
from Eq. (7), Method 1 [Eq. (4)], Method 2 [Eq. (6)], and Method 2 including
neighbors (only for masses >2.3 g). N.B. The y-axis is plotted using a
logarithmical scale.
interest to investigate these different sources of uncertainty in
detail.
The obtained absorbed doses from the whole-volume and
the maximum-voxel methods ranged between 2 and 176 Gy
(mean 40 Gy) and 2 and 145 Gy (mean 34 Gy), respectively.
As shown in Fig. 5, the difference obtained for each individual
patient is small in relation to the wide range of absorbed doses.
In Fig. 4, for the spheres of known volume and activity, it is
seen that the ratio of absorbed doses from the two methods
tends toward a value of approximately 1.2. Likewise for
patient data, the mean ratio is 1.2. This difference can be
explained by the S-values used for absorbed dose calculation.
Figure 6 shows the absorbed dose per cumulated activity,
as function of mass, from Eq. (4), based on unit density
spheres, and Eq. (6), based on voxel S-values. In addition,
values are shown for voxel S-values where the absorbed-dose
contribution from neighboring voxels is taken into account,
as provided in the study by Lanconelli et al.26 For this
last method, only masses higher than 2.3 g are considered,
corresponding to 27 voxels including the 6 closest neighbors,
the 12 second neighbors, and the 8 third neighbors. As a fourth
source of comparison, the method given in guidelines for
radio-iodine therapy of DTC from the European Association
of Nuclear Medicine (EANM)2 is included, where the equation
for the absorbed dose to sites with 131I uptake is the
following:
D = A˜sSth← th
mref,th
ms
, (7)
where Sth← th is the MIRD defined S-value for thyroid self-
irradiation (5.652× 10−3 Gy MBq−1 h−1 33), mref,th is the
reference mass of the thyroid (20.7 g), and ms is the site
mass.
As shown, the S-values used in Eq. (7) are slightly
higher than the unit-density sphere S-values, used in whole-
volume dosimetry (Method 1), although differences are subtle.
Voxel-based S-values, used in maximum-voxel dosimetry
(Method 2), are slightly lower, with increasing differ-
ences as the mass increases. When including the contribu-
tion from the neighboring voxels, the S-values are nearly
identical.
Another reason for the observed differences between
whole-volume and maximum-voxel dosimetry is the integra-
tion of the time-activity values to cumulated activity. As seen
in Fig. 2, the activity concentrations for each time-point are
consistent, but even small deviations from the identity line in
each SPECT/CT acquisition can result in large differences in
effective half-lives as shown in Fig. 3, especially for higher
effective half-lives. In this study, it was not feasible to perform
the third acquisition in the same day for all patients, but
the differences in the effective half-lives between Methods
1 and 2 did not correlate with the day of the third acquisition.
Thus, any extra time-point acquired during the washout phase
would help to achieve less variability in the effective half-lives
between Methods 1 and 2.
There is an increased evidence in radionuclide therapy of
a dose-effect correlation.34 In DTC treatments, dose-effect
correlations have been reported but there is no consensus on
the remnant absorbed dose above which there is a higher
probability to achieve a successful ablation.11,14,18 If the
administered activity could be tailored to reach a predefined
absorbed dose to thyroid remnants, adequate for successful
ablation, then excess levels of 131I-NaI could be avoided, thus
minimizing the probability of unwanted side-effects, such as
sialadenitis and xerostomia35 and second primary cancers.36,37
In addition, the number of patients with recurring or persistent
disease, which can entail the loss of iodine avidity, could
possibly be minimized.38 A reduction of the administered
activity would also be clearly beneficial for the radiolog-
ical protection of caregivers and comforters. Pretreatment
dosimetry with a tracer may be considered an increased
economic cost of the treatment. However, Maxon et al.13
showed that tailoring the absorbed dose to the individual
patient may in many cases decrease the administered amount
of activity. This may reduce the hospitalization time, and
some treatments could even be performed on an outpatient
basis, thereby decreasing the overall cost of the treatment. The
administration of a tracer has been reported to cause the so-
called thyroid stunning.39,40 Lassmann et al.,16 recommended
not to administer any amount of 131I before treatment because
its uptake was notably reduced after administering a tracer
of 74 MBq. However, this effect is still unclear41 and it has
been explained as a reduced expression of NIS (Ref. 42) or
alternatively as a result of cell killing.43 In order to avoid the
stunning effect, the use of 124I as a tracer (decays modes are
electron capture and positron emission) seems a promising
alternative because the self-irradiation of the remnant would
be avoided.20 Further dosimetric studies on this subject are
thus warranted. The dosimetric method used in this study can
be implemented at most centers treating DTC, relying only
on the availability of SPECT/CT scanning, access to basic
quality-control phantoms and software to analyze DICOM
images. Future dose–response correlation studies may need
to take into account the disease stage, the thyroid remnants
mass left after surgery,14 and the patient preparation before
treatment, including the protocols for surgery and hormone
withdrawal or stimulation with rhTSH.44
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5. CONCLUSIONS
In this study, SPECT/CT dosimetry in DTC patients,
based on the whole-remnant and the maximum-voxel, is
described and compared. Generally, consistent absorbed doses
are obtained from the two methods, although the maximum-
voxel method yields values that are on average 20% lower than
the whole-remnant method due to differences in the S-values.
In some cases, differences also result from the estimated
effective half-lives, indicating that additional acquisition time-
points are warranted. Practically, for the future, either of the
dosimetry methods is useful. In order to rule out the difference
related to the S-values, the absorbed dose derived from the
maximum-voxel method would need to be multiplied by a
factor dependent on remnant mass, which can be as high
as 1.2.
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APPENDIX A: OBTENTION OF THE SITE VOLUME
FROM RECOVERY COEFFICIENTS
This section is included to show that, given the assumption
of homogenous activity concentration, recovery coefficients
are applicable for both whole-volume and maximum-voxel
dosimetry.
For a spherical object with volume vo and homogenous
activity concentration [A], the contained activity is given by
A= [A]vo. (A1)
If this object is imaged by an ideal system, i.e., with ideal
spatial resolution, the activity can be described as
A=
1
ε
Ct =
1
ε
coNo, (A2)
where Ct is the total count rate in the object, co is the count
rate per voxel, and No is the number of object voxels. The
object volume is given by
vo =∆vNo =∆v
Ct
co
, (A3)
where ∆v is the voxel volume. In a real imaging system,
the limited spatial resolution affects the count distribution.
For a sphere with a diameter large in comparison with the
FWHM of the PSF, the maximum voxel count-rate, cm, gives
a good estimate of co, i.e., the voxel count-rate in absence of
resolution effects. The volume vo is then approximately equal
to the apparent object volume, va, i.e., the volume as measured
F. 7. Experimentally determined recovery coefficients (RCs) from the IEC
phantom data. Open symbols show RCs as function of true sphere volume,
whereas filled symbols are RCs as function of the apparent volumes. Dashed
line is a fitted expression in Eq. (A6).
in the image when it is affected by limited spatial resolution,
va =∆v
Ct
cm
. (A4)
For smaller spheres, limited by the spatial resolution, cm
underestimates co, while va overestimates vo. In Appendix B,
va are shown, when estimated using Eq. (A4), as function of
vo for simulated data and different spatial resolutions.
The recovery coefficient, RC, is defined as the ratio of
the measured and true activity concentrations. Following the
above equations, the RC describes the ratio of count rates or
volumes (see Appendix C) according to
RC=
cm
co
=
vo
va
. (A5)
Appendix B shows RCs for simulated data and different spatial
resolutions, as function of both the true and the apparent
sphere volumes.
For analysis of the patient SPECT images in this study,
the RC was determined from the IEC phantom data by
determining va according to Eq. (A4) and applying Eq. (A5),
i.e., the ratio of the true and apparent sphere volumes.
Figure 7 shows the experimentally determined RC. In order
to interpolate between data points, an equation was fitted to
the RC-versus-va data, taking the SDs into account, using the
following sigmoid function:
RC(va)= 11+exp(−α(va− β)) , (A6)
where α and β are fit parameters.
APPENDIX B: VALUES OF RECOVERY
COEFFICIENTS FROM COMPUTER SIMULATIONS
Figure 8 shows results of computer simulations mimicking
the effect of different spatial resolutions. It is seen that the
overestimate in the apparent volume, va, for small volumes is
more pronounced when the spatial resolution is poor. For
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F. 8. Results from computer simulations for FWHMs of 13.3 mm (red), 17.7 mm (green), and 22.1 mm (blue). (A) The apparent volume, va, obtained by
application of Eq. (A4), as function of true sphere volumes, vo. Identity line is dashed. (B) Recovery coefficients, determined using Eq. (A6), plotted both versus
true sphere volumes (dashed lines) and apparent volumes (solid lines). (See color online version.)
larger volumes, va converges toward vo, and the recovery
coefficient converges to a value of 1.
APPENDIX C: ACTIVITY PER VOXEL
The recovery coefficient, RC, in Eq. (A5), is described as
RC=
[A]meas
[A]true =
A/va
A/vo
=
vo
va
=
cm
co
. (C1)
The expression for the activity per voxel in Eq. (5) is derived
according to
Avx= [A]∆v = A
vo
∆v =
1
ε
Ct
vo
∆v =
1
ε
co
∆v
∆v =
1
ε
cm
RC(va) . (C2)
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